Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Lukac

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
ESMO Open|August 18, 2018
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS studyAntoine Thiery-Vuillemin, Mads Hvid Poulsen, Edouard Lagneau, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
BMC Cancer|January 16, 2019
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort studyMartin Boegemann, Sara Khaksar, Guillaume Bera, et al.
BMC Cancer|July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2005
Forest response to elevated CO2 is conserved across a broad range of productivityRichard J Norby, Evan H Delucia, Birgit Gielen, et al.
The New Phytologist|June 7, 2017
Adaptive root foraging strategies along a boreal-temperate forest gradientIvika Ostonen, Marika Truu, Heljä-Sisko Helmisaari, et al.
Trends in Plant Science|December 4, 2009
Challenges in elevated CO2 experiments on forests, Carlo Calfapietra, Elizabeth A Ainsworth, et al.
Nature Ecology & Evolution|January 17, 2018
Genotypic variability enhances the reproducibility of an ecological studyAlexandru Milcu, Ruben Puga-Freitas, Aaron M Ellison, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
ESMO Open|August 18, 2018
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS studyAntoine Thiery-Vuillemin, Mads Hvid Poulsen, Edouard Lagneau, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
BMC Cancer|January 16, 2019
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort studyMartin Boegemann, Sara Khaksar, Guillaume Bera, et al.
BMC Cancer|July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2005
Forest response to elevated CO2 is conserved across a broad range of productivityRichard J Norby, Evan H Delucia, Birgit Gielen, et al.
The New Phytologist|June 7, 2017
Adaptive root foraging strategies along a boreal-temperate forest gradientIvika Ostonen, Marika Truu, Heljä-Sisko Helmisaari, et al.
Trends in Plant Science|December 4, 2009
Challenges in elevated CO2 experiments on forests, Carlo Calfapietra, Elizabeth A Ainsworth, et al.
Nature Ecology & Evolution|January 17, 2018
Genotypic variability enhances the reproducibility of an ecological studyAlexandru Milcu, Ruben Puga-Freitas, Aaron M Ellison, et al.
Pageof 5